Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,177
archived clinical trials in
Orthopedic

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute
851
mi
from
Phoenix, AZ
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Uc Irvine Medical Center
1154
mi
from
Orange, CA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Uc Irvine Medical Center
1154
mi
from
Orange, CA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
1340
mi
from
San Francisco, CA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Florida Medical Center
1049
mi
from
Gainesville, FL
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Florida Medical Center
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
1112
mi
from
Tampa, FL
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital
803
mi
from
Atlanta, GA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
429
mi
from
Iowa City, IA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
429
mi
from
Iowa City, IA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Kentucky Medical Center
725
mi
from
Lexington, KY
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Kentucky Medical Center
725
mi
from
Lexington, KY
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Ochsner Neuroscience Institute
694
mi
from
New Orleans, LA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Ochsner Neuroscience Institute
694
mi
from
New Orleans, LA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Medical Center
1408
mi
from
Worcester, MA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Medical Center
1408
mi
from
Worcester, MA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Michigan Medical Center
828
mi
from
Ann Arbor, MI
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Michigan Medical Center
828
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
552
mi
from
Minneapolis, MN
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
415
mi
from
Saint Louis, MO
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Neurology Associates PC
219
mi
from
Lincoln, NE
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Neurology Associates PC
219
mi
from
Lincoln, NE
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Beth Israel
1287
mi
from
New York, NY
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Beth Israel
1287
mi
from
New York, NY
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
976
mi
from
Winston-Salem, NC
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
810
mi
from
Columbus, OH
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
810
mi
from
Columbus, OH
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
The Penn Comprehensive ALS Center
1225
mi
from
Philadelphia, PA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
The Penn Comprehensive ALS Center
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
1225
mi
from
Philadelphia, PA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
345
mi
from
Dallas, TX
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
345
mi
from
Dallas, TX
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
571
mi
from
San Antonio, TX
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
ALS Center at the Swedish Neuroscience Institute
1409
mi
from
Seattle, WA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
ALS Center at the Swedish Neuroscience Institute
1409
mi
from
Seattle, WA
Click here to add this to my saved trials
Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes
Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes? A Prospective Randomized Sham-Control Trial With 6 Month Follow Up
Status: Enrolling
Updated:  12/31/1969
Anesthesiology Pain Medicine Center
611
mi
from
Chicago, IL
Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes
Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes? A Prospective Randomized Sham-Control Trial With 6 Month Follow Up
Status: Enrolling
Updated: 12/31/1969
Anesthesiology Pain Medicine Center
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Pregnancy in Osteogenesis Imperfecta (OI) Registry
Pregnancy in Osteogenesis Imperfecta (OI) Registry
Status: Enrolling
Updated:  12/31/1969
RDCRN Data Management and Coordinating Center, University of South Florida
1117
mi
from
Tampa, FL
Pregnancy in Osteogenesis Imperfecta (OI) Registry
Pregnancy in Osteogenesis Imperfecta (OI) Registry
Status: Enrolling
Updated: 12/31/1969
RDCRN Data Management and Coordinating Center, University of South Florida
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Research Site
683
mi
from
Birmingham, AL
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Research Site
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Research Site
1055
mi
from
Jacksonville, FL
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Research Site
1055
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Research Site
1148
mi
from
Baltimore, MD
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Research Site
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
1444
mi
from
Boston, MA
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
554
mi
from
Saint Paul, MN
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
554
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
415
mi
from
Saint Louis, MO
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
524
mi
from
Albuquerque, NM
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
524
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
728
mi
from
Cincinnati, OH
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
728
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
1383
mi
from
Portland, OR
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
1383
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
971
mi
from
Pittsburgh, PA
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Research Site
618
mi
from
Nashville, TN
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Research Site
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
569
mi
from
Houston, TX
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated:  12/31/1969
Mereo Investigator Site
mi
from
Toronto,
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Protocol Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804).
Status: Enrolling
Updated: 12/31/1969
Mereo Investigator Site
mi
from
Toronto,
Click here to add this to my saved trials
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
1288
mi
from
New York, NY
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
1288
mi
from
New York, NY
Click here to add this to my saved trials
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Gluten Free Diet for GVHD Prophylaxis
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Gluten Free Diet for GVHD Prophylaxis
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI
Effects of Acute Intermittent Hypoxia (AIH) on Metabolism and Dysglycemia, in Overweight/Obese Persons With Spinal Cord Injuries (SCI)
Status: Enrolling
Updated:  12/31/1969
The Miami Project to Cure Paralysis
1321
mi
from
Miami, FL
Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI
Effects of Acute Intermittent Hypoxia (AIH) on Metabolism and Dysglycemia, in Overweight/Obese Persons With Spinal Cord Injuries (SCI)
Status: Enrolling
Updated: 12/31/1969
The Miami Project to Cure Paralysis
1321
mi
from
Miami, FL
Click here to add this to my saved trials
MR Guided Focused Ultrasound for Treatment of Neuropathic Pain
Phase 1 Clinical Trial for MR Guided Focused Ultrasound (FUS) Thalamotomy of Central Lateral Thalamic Nucleus for the Treatment of Neuropathic Pain
Status: Enrolling
Updated:  12/31/1969
University of Maryland School of Medicine and University of Maryland Medical Systems
1148
mi
from
Baltimore, MD
MR Guided Focused Ultrasound for Treatment of Neuropathic Pain
Phase 1 Clinical Trial for MR Guided Focused Ultrasound (FUS) Thalamotomy of Central Lateral Thalamic Nucleus for the Treatment of Neuropathic Pain
Status: Enrolling
Updated: 12/31/1969
University of Maryland School of Medicine and University of Maryland Medical Systems
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?
Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
552
mi
from
Minneapolis, MN
Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?
Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
A Prospective, Randomized, Double Blinded Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
1288
mi
from
New York, NY
A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
A Prospective, Randomized, Double Blinded Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
1288
mi
from
New York, NY
Click here to add this to my saved trials
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Status: Enrolling
Updated:  12/31/1969
Texas Diabetic Institute
576
mi
from
San Antonio, TX
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Status: Enrolling
Updated: 12/31/1969
Texas Diabetic Institute
576
mi
from
San Antonio, TX
Click here to add this to my saved trials
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated:  12/31/1969
Andrews Research and Education Foundation, Inc.
794
mi
from
Gulf Breeze, FL
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated: 12/31/1969
Andrews Research and Education Foundation, Inc.
794
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated:  12/31/1969
Methodist Sports Medicine
643
mi
from
Indianapolis, IN
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated: 12/31/1969
Methodist Sports Medicine
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
1289
mi
from
New York, NY
Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study
Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
1289
mi
from
New York, NY
Click here to add this to my saved trials